News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aegerion Pharmaceuticals, Inc. (AEGR) Gets DOJ Subpoena Over Marketing Of Cholesterol Drug


1/10/2014 6:37:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Aegerion Pharmaceuticals Inc said on Thursday that it received a subpoena from the U.S. Department of Justice, requesting documents related to the marketing and sale of its cholesterol drug Juxtapid in the United States. Aegerion shares fell more than 12 percent in extended trading. Juxtapid was approved by U.S. health regulators in December 2012 to treat patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic disease that impairs the function of the receptor responsible for removing LDL-C or "bad" cholesterol from the body.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at BusinessWeek
Read at ABC News
Read at Forbes

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES